Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2584MR)

This product GTTS-WQ2584MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2584MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2897MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ13494MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7226MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7375MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ13633MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ4140MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ10105MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ1620MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW